Most Read Articles
Pearl Toh, 3 days ago
Not only does the CGRP* inhibitor galcanezumab show sustained efficacy in migraine patients, long-term treatment does not come with excess cardiovascular (CV) risk, according to studies presented at the AAN 2021 Annual Meeting.
01 Apr 2021
Migraine and headache are common ailments of people living in the modern era. Dr Jon Marshall of The Singapore Headache and Migraine Clinic shares his insights with Pearl Toh on how to manage migraine and headache using non-pharmaceutical strategies, with a focus on the manual medicine approach.
Elvira Manzano, 3 days ago
An investigational transdermal amphetamine patch worn for 9 hours on the hip appeared effective in paediatric patients with attention deficit-hyperactivity disorder (ADHD) in a phase II, two-part trial.
Tristan Manalac, 5 days ago
Visceral fat area is the strongest indicator of mobility disability among obese, community-dwelling, older adults, according to a recent Singapore study.

Hemospray highly effective for controlling GI bleeding, but not suited for long-term use

3 days ago

A recently approved hemostatic powder, Hemospray, has demonstrated robust effectiveness in achieving immediate hemostasis in gastrointestinal (GI) bleeding, reports a study.

However, Hemospray is not suited for definitive long-term therapy because of its significantly high rebleeding rates.

The investigators conducted a systematic review and meta-analysis to assess the clinical performance of Hemospray in the management of GI bleeding. Multiple databases were searched from inception through March 2019 to identify studies reporting on the clinical outcomes of Hemospray in GI bleeding.

Nineteen studies including a total of 814 patients were identified. Of the patients, 212 were treated with Hemospray as monotherapy and 602 with Hemospray and conventional hemostatic techniques.

Overall pooled clinical success, the primary outcome, after the application of Hemospray was 92 percent (95 percent confidence interval [CI], 87–96; I2, 70.4 percent). The secondary outcome of pooled early rebleeding rate after application of Hemospray was 20 percent (95 percent CI, 16–26; I2, 54 percent), while the overall pooled delayed rebleeding rate was 23 percent (95 percent CI, 16–31; I2, 34.9 percent).

No statistical difference was noted in clinical success (relative risk [RR], 1.02, 95 percent CI, 0.96–1.08; p=0.34) and early rebleeding (RR, 0.89, 95 percent CI, 0.75–1.07; p=0.214) in studies that compared the use of Hemospray as monotherapy relative to combination therapy with conventional treatment.

“Hemospray is a new hemostatic powder recently approved for endoscopic hemostasis in GI bleeding,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
Not only does the CGRP* inhibitor galcanezumab show sustained efficacy in migraine patients, long-term treatment does not come with excess cardiovascular (CV) risk, according to studies presented at the AAN 2021 Annual Meeting.
01 Apr 2021
Migraine and headache are common ailments of people living in the modern era. Dr Jon Marshall of The Singapore Headache and Migraine Clinic shares his insights with Pearl Toh on how to manage migraine and headache using non-pharmaceutical strategies, with a focus on the manual medicine approach.
Elvira Manzano, 3 days ago
An investigational transdermal amphetamine patch worn for 9 hours on the hip appeared effective in paediatric patients with attention deficit-hyperactivity disorder (ADHD) in a phase II, two-part trial.
Tristan Manalac, 5 days ago
Visceral fat area is the strongest indicator of mobility disability among obese, community-dwelling, older adults, according to a recent Singapore study.